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The cellular origins of cancer have long been debated. Work
indicating the existence of a rare stem cell for acute leukemia
was followed by a number of reports of relatively rare stem
cells for a number of cancers. Other work has challenged the
concept of cancer stem cells being a rare repopulating cell for
cancer or providing a promising target for chemotherapy or
immunotherapy. A balanced view here may be that there may
be a continuum of Bstemness^ with early cancers having rare
stem cells while with progression , i.e. most solid tumors, most
of the cancer cells are in fact stem cells. In this latter case there
would be no advantage to defining these cells. Thus far thera-
peutic application of cancer stem cell directed therapy has been
disappointing. There is also longstanding and abundant infor-
mation on the role of microenvironment in carcinogenesis. This
bring up the issues of whether cancer cell mutations or micro
environmental influences are predominant in carcinogenesis.
The area of aging and stem cells interfaces with carcino-
genesis as the latter progressively increases with age. The
increasing clonal nature of blood stem cells with aging is perti-
nent here. Many studies have suggested interesting changes in
hematopoietic stem cell numbers and function but have not taken
into account the issues of the stem cell continuum and baseline
stem cell hematopoiesis. Major issue are whether aging effects
can be reversed or manipulated and what role the systemic
effects of aging have on neoplastic hematopoietic diseases.
The section on Cancer stem cells and Aging provides a
forum for the exchange of ideas and results from areas
pertaining to cancer stem cells and carcinogenesis in general
and the impact of aging on stem cell number and function and
neoplastic potential. We will emphasize
– The definition of cancer stem cells;
– The characterization as to total phenotype of putative
cancer stem cells;
– The model systems available for study;
– The regulation of putative cancer stem cells:-the thera-
peutic implication of cancer stem cells;
– The changes in hematopoiesis and hematopoietic stem
cells with aging;
– The nature of clonal hematopoiesis with aging;
– The study of different stem cell models with aging;
– The capacity to modulate aging effects of hematopoiesis;
– The implications for hematologic malignancies with re-
gard to aging hematopoietic stem cells;
– The therapeutic implications of aging hematopoietic stem
cell populations
We look forward to receiving your high-quality submis-
sions to our journal and also welcome your feedback and
opinions on the new structure and other future changes.
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